Poster: Artificial Intelligence predicts cell proliferation from DAPI images of (hISC)-derived colorectal cancer model

Format:

Joint collaboration with Ryvu Therapeutics

About the poster

This poster, presented at SBI2 2024 and created in collaboration between Ardigen and Ryvu Therapeutics, showcases an innovative AI-based approach for predicting cancer cell proliferation from microscopy images. Using a deep learning model trained on DAPI-stained nuclei images, the team demonstrates that proliferation can be assessed without the need for EdU staining, significantly reducing cost and increasing throughput. The method maintains high accuracy across different cell lines, offering a promising tool for phenotypic drug screening in complex co-culture systems.

You might be also interested in:

Accelerating biomarker discovery through omic data integration into drug screens
Accelerating biomarker discovery through omic data integration
Two scientists observing AI-driven cell analysis on a digital screen, representing decision-making in biotech innovation.
Build or Buy? Strategic Considerations for Biotech Companies Implementing AI Solutions
biotech US market
AI in biotech: What the US market got right (and what it’s still learning)
From Data Chaos to Drug Discovery – Ardigen Talk at NextGen Omics Conference

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!